Prelude Therapeutics (PRLD) Non-Current Assets (2019 - 2026)

Prelude Therapeutics has reported Non-Current Assets for 8 years, with the latest figure at $35.0 million in Q1 2026.

• Quarterly Non-Current Assets fell 9.8% year-over-year to $35.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $145.1 million (down 9.79% YoY) and the FY2025 annual result came in at $35.6 million, down 10.09% from the prior year.
• Non-Current Assets eased to $35.0 million in Q1 2026 per PRLD's latest filing, from $35.6 million in the prior quarter.
• Over five years, Non-Current Assets peaked at $42.1 million in Q4 2023 and troughed at $10.4 million in Q2 2022.
• A 5-year average of $30.0 million and a median of $35.6 million in 2025 frame the typical range for Non-Current Assets.
• The sharpest annual moves came in 2022 and 2025: Non-Current Assets jumped 190.11% in 2022, then decreased 10.8% in 2025.
• Over 5 years, Non-Current Assets stood at $16.1 million in 2022, then jumped by 161.02% to $42.1 million in 2023, then fell by 5.84% to $39.6 million in 2024, then dropped by 10.09% to $35.6 million in 2025, then retreated by 1.61% to $35.0 million in 2026.
• According to Business Quant data, Non-Current Assets over the past three periods registered $35.0 million, $35.6 million, and $36.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.